（文章来源：北京商报） 北京商报讯（记者丁宁）11月28日晚间，新华医疗（600587）发布公告称，公司全资子公司华佗国际发 展有限公司（以下简称"华佗国际"）拟通过公开市场交易方式出售华检医疗控股有限公司（以下简 称"华检医疗"）不超过5%的股份。 新华医疗表示，为聚焦核心主业发展，提升资产运营效率，公司全资子公司华佗国际拟通过公开市场交 易方式（含连续竞价交易、集合竞价交易和大宗交易等某一种或相结合方式）出售华检医疗不超过5% 的股份，华佗国际将基于对华检医疗股票价格的合理判断，根据华检医疗股票价格波动情况及资本市场 整体趋势，逐步实施减持计划，交易价格尚无法确定。 ...

Core Viewpoint - The company plans to sell 62% of its subsidiary Taiyuan Pharmaceutical Co., Ltd. to Shanxi Tongxiang Times Technology Co., Ltd. for RMB 87.1887 million, which will result in a significant change in ownership structure and financial reporting [1][2] Group 1: Transaction Details - After the transaction, Shanxi Tongxiang will hold 95% of Taiyuan Pharmaceutical, while the company will retain 5%, leading to Taiyuan Pharmaceutical being excluded from the company's consolidated financial statements [1][2] - The transaction is based on an asset-based valuation method, with Taiyuan Pharmaceutical's net asset book value at RMB 54.1061 million and a total equity valuation of RMB 141 million, resulting in an appraisal increment of RMB 86.5209 million and an increase rate of 159.91% [1] Group 2: Financial Impact - The company anticipates that the transaction will increase its profit by approximately RMB 59 million for the fiscal year 2025, subject to final audited figures [1] - Taiyuan Pharmaceutical reported revenues of RMB 9.0671 million and RMB 390,400 for the years 2024 and January to August 2025, respectively, with net losses of RMB 15.3785 million and RMB 614,730 during the same periods [1] Group 3: Operational Changes - Employee placement at Taiyuan Pharmaceutical has been completed, and its management will be nominated by Shanxi Tongxiang after the transaction [2] - The company confirms that there are no guarantees or financial management arrangements involving Taiyuan Pharmaceutical, and there will be no related party transactions or competition issues post-transaction [2] Group 4: Company Performance - The company reported a third-quarter revenue of RMB 569 million, a year-on-year decrease of 16.01%, and a net profit of RMB 40.6971 million, down 26.22% [2] - For the first three quarters, the company achieved revenues of RMB 1.709 billion, a decline of 19.46%, and a net profit of RMB 215 million, down 8.44% [2]

Core Viewpoint - Nanshan Holdings (002314) is actively engaging in multiple core businesses through its subsidiaries, addressing historical and strategic reasons for the presence of minority shareholders in key subsidiaries like Baowan Logistics and Shengbaowang [1] Group 1: Business Strategy - The company operates in capital-intensive sectors such as real estate development, often utilizing joint ventures to attract partners for co-investment, which aligns with common industry practices [1] - Nanshan Holdings adheres to market-oriented principles in its investment and operational activities, ensuring fair and reasonable distribution of interests among all parties involved [1] Group 2: Future Outlook - The company plans to continuously optimize its capital structure, enhance asset operational efficiency, and increase contributions to shareholder value in the future [1]

Core Viewpoint - Fosun Pharma is planning to divest 100% equity of Shanghai Clone to enhance focus on core business and improve asset operation efficiency [1] Group 1: Transaction Structure - Fosun Pharma's subsidiary, Fosun Pharma Industry, and partners intend to establish a special fund with a target capital of RMB 547 million, with contributions from various parties [2] - The fund will be structured with Fosun Pharma Industry contributing RMB 54.6 million, while Zhonghui Life will contribute RMB 491.4 million, resulting in respective ownership stakes of 9.98% and 89.84% [2] - Following the establishment of the fund, Fosun Pharma Industry will transfer 100% equity of Shanghai Clone for a consideration not exceeding RMB 1.256 billion [2] Group 2: Asset Details - The main asset of Shanghai Clone includes state-owned land use rights and property ownership located at 1289 Yishan Road, Xuhui District, Shanghai, covering an area of 19,944 square meters with a building area of 45,238.55 square meters [2] - After the transfer, the group will no longer hold equity in Shanghai Clone but will continue to lease part of the property for operational purposes [3] - Shanghai Fushun, a subsidiary, will provide asset management services for Shanghai Clone post-transfer [3]

Core Viewpoint - Fosun Pharma's subsidiary plans to transfer 100% equity and debt of Shanghai Clone for a consideration not exceeding 1.256 billion yuan, aiming to focus on core business and enhance asset operation efficiency [1] Group 1: Transaction Details - The transaction involves a total consideration of up to 1.256 billion yuan [1] - The special fund plans to raise 547 million yuan, with Fosun Pharma contributing 54.6 million yuan, holding a 9.98% share of the fund [1] - After the transaction, Fosun Pharma will no longer hold equity in Shanghai Clone but will continue to lease part of the property for operational purposes [1] Group 2: Strategic Intent - The proceeds from the transfer will be used for continued investment in innovative drug business [1]

Transaction Overview - The company plans to publicly transfer 41.0071% equity stake in Chongqing Tiantai Energy Group Co., Ltd. to enhance asset operation efficiency and optimize strategic layout [1][2] - The minimum transfer price is set at 640.7596 million yuan, based on the valuation report from Zhongrui Shilian Asset Appraisal Group [1][5] Purpose and Rationale - The transaction aims to convert equity into more liquid funds, improving cash flow efficiency and aligning with the interests of the company and all shareholders [2][6] Board Approval - The board of directors approved the equity transfer proposal with a unanimous vote of 13 in favor [2][9] Transaction Process - The transaction will be conducted through a public listing, with the buyer and final transaction price yet to be determined [2][4] Target Company Information - Chongqing Tiantai Energy Group was established on December 25, 2016, with a registered capital of 245.2325 million yuan, focusing on power production and sales, among other activities [4][5] - As of March 31, 2025, Tiantai Energy reported total assets of approximately 4.42 billion yuan and net assets of about 1.10 billion yuan [4][5] Valuation and Pricing - The valuation of Tiantai Energy's 100% equity is approximately 1.5625576 billion yuan, with the 41.0071% stake valued at 640.7596 million yuan, reflecting a 123.60% appreciation [5][8] Impact on the Company - Successful completion of the transaction is expected to yield an estimated investment return of about 190 million yuan, positively affecting the company's financial status and operational results [6][9]

Core Viewpoint - The company plans to suspend and cold-repair its float glass production line (450T/D) and professionally dispose of 124.9 tons of tin ingots, aiming to optimize production line efficiency and improve asset operation efficiency [1] Group 1 - The board of directors approved the asset disposal plan on June 30, 2025 [1] - The assessed value of the disposed tin ingots is 31.0172 million yuan [1] - The asset disposal does not constitute a related party transaction or a major asset restructuring [1]

Transaction Overview - The company plans to transfer 95% equity of Shandong Zhiyou Network Security Technology Co., Ltd. and related debts through public listing to optimize asset structure, improve cash flow, and enhance asset operation efficiency [1] - The total transfer price is set at no less than RMB 20,530,001 [1] Transaction Progress - The public listing commenced on April 16, 2025, and will end on May 18, 2025, with the starting price based on the assessed value [1]